Dianthus Therapeutics, Inc. /DE/ Operating Leases, Rent Expense, Net
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Operating Leases, Rent Expense, Net of $6.20 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeasesRentExpenseNet · last filed 2022-03-08
- Dianthus Therapeutics, Inc. /DE/ operating leases, rent expense, net for the quarter ending 2021-12-31 was $1.60M, a 0.00% change year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating leases, rent expense, net for the quarter ending 2021-09-30 was $1.50M, a 0.00% change year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating leases, rent expense, net for the quarter ending 2021-06-30 was $1.60M, a 0.00% change year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating leases, rent expense, net for the quarter ending 2021-03-31 was $1.50M, a 6.25% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating leases, rent expense, net for fiscal 2021 was $6.20M, a 0.00% change from fiscal 2020.
- Dianthus Therapeutics, Inc. /DE/ operating leases, rent expense, net for fiscal 2020 was $6.20M, a 1.64% increase from fiscal 2019.
- Dianthus Therapeutics, Inc. /DE/ operating leases, rent expense, net for fiscal 2019 was $6.10M, a 38.64% increase from fiscal 2018.
- Dianthus Therapeutics, Inc. /DE/ operating leases, rent expense, net for fiscal 2018 was $4.40M, a 300.00% increase from fiscal 2017.
| Period end | Operating Leases, Rent Expense, Net 3 month | Operating Leases, Rent Expense, Net 3 month as first filed | Operating Leases, Rent Expense, Net 6 month | Operating Leases, Rent Expense, Net 9 month | Operating Leases, Rent Expense, Net 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $3.10M derived: sum of 2 quarters · filed 2022-03-08 | $4.70M derived: sum of 3 quarters · filed 2022-03-08 | $6.20M 10-K · filed 2022-03-08 | |
| 2021-09-30 | $1.50M 10-Q · filed 2021-11-04 | $3.10M derived: sum of 2 quarters · filed 2021-11-04 | $4.60M 10-Q · filed 2021-11-04 | $6.20M derived: sum of 4 quarters · filed 2022-03-08 | |
| 2021-06-30 | $1.60M 10-Q · filed 2021-08-05 | $3.10M 10-Q · filed 2021-08-05 | $4.70M derived: sum of 3 quarters · filed 2022-03-08 | $6.20M derived: sum of 4 quarters · filed 2022-03-08 | |
| 2021-03-31 | $1.50M 10-Q · filed 2021-05-06 | $3.10M derived: sum of 2 quarters · filed 2022-03-08 | $4.60M derived: sum of 3 quarters · filed 2022-03-08 | $6.20M derived: sum of 4 quarters · filed 2022-03-08 | |
| 2020-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $3.10M derived: sum of 2 quarters · filed 2022-03-08 | $4.70M derived: sum of 3 quarters · filed 2022-03-08 | $6.20M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $1.50M 10-Q · filed 2021-11-04 | $3.10M derived: sum of 2 quarters · filed 2021-11-04 | $4.60M 10-Q · filed 2021-11-04 | $6.20M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $1.60M 10-Q · filed 2020-08-06 | $3.10M 10-Q · filed 2021-08-05 | $4.70M derived: sum of 3 quarters · filed 2021-08-05 | $6.20M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $1.60M 10-Q · filed 2021-08-05 | $1.50M 10-Q · filed 2020-05-07 | $3.10M derived: sum of 2 quarters · filed 2021-08-05 | $4.60M derived: sum of 3 quarters · filed 2021-08-05 | $6.20M derived: sum of 4 quarters · filed 2021-08-05 |
| 2019-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $3.00M derived: sum of 2 quarters · filed 2021-03-03 | $4.60M derived: sum of 3 quarters · filed 2021-03-03 | $6.10M 10-K · filed 2021-03-03 | |
| 2019-09-30 | $1.50M 10-Q · filed 2020-11-05 | $3.10M derived: sum of 2 quarters · filed 2020-11-05 | $4.60M 10-Q · filed 2020-11-05 | $6.10M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2019-06-30 | $1.60M 10-Q · filed 2020-08-06 | $3.10M 10-Q · filed 2020-08-06 | $4.60M derived: sum of 3 quarters · filed 2020-08-06 | $6.40M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | $1.50M 10-Q · filed 2020-05-07 | $3.00M derived: sum of 2 quarters · filed 2020-05-07 | $4.80M derived: sum of 3 quarters · filed 2020-05-07 | $5.60M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $3.30M derived: sum of 2 quarters · filed 2020-03-03 | $4.10M derived: sum of 3 quarters · filed 2020-03-03 | $4.40M 10-K · filed 2020-03-03 | |
| 2018-09-30 | $1.80M 10-Q · filed 2019-11-13 | $2.60M derived: sum of 2 quarters · filed 2019-11-13 | $2.90M 10-Q · filed 2019-11-13 | $3.20M derived: sum of 4 quarters · filed 2020-03-03 | |
| 2018-06-30 | $800.00K 10-Q · filed 2019-08-08 | $1.10M 10-Q · filed 2019-08-08 | $1.40M derived: sum of 3 quarters · filed 2020-03-03 | $1.70M derived: sum of 4 quarters · filed 2020-03-03 | |
| 2018-03-31 | $300.00K 10-Q · filed 2019-05-09 | $600.00K derived: sum of 2 quarters · filed 2020-03-03 | $900.00K derived: sum of 3 quarters · filed 2020-03-03 | $1.20M derived: sum of 4 quarters · filed 2020-03-03 | |
| 2017-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $600.00K derived: sum of 2 quarters · filed 2020-03-03 | $900.00K derived: sum of 3 quarters · filed 2020-03-03 | $1.10M 10-K · filed 2020-03-03 | |
| 2017-09-30 | $300.00K 10-Q · filed 2018-11-08 | $600.00K derived: sum of 2 quarters · filed 2018-11-08 | $800.00K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $300.00K 10-Q · filed 2018-08-09 | $500.00K 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |